论文部分内容阅读
目的:探讨耐药基因PgP、ToPo-Ⅱ、GST-π和核增殖细胞抗原Ki-67在肺癌中的表达及其临床病理学意义。方法:应用免疫组织化学(SP法)检测58例肺癌中PgP、ToPo-Ⅱ、GST-π和增殖细胞核抗原Ki-67的表达情况。结果:PgP、ToPo-Ⅱ、GST-π在58例肺癌组织中的阳性率分别为17.1%、79.1%、72.3%;其中ToPo-Ⅱ在鳞癌和小细胞癌中的表达明显高于腺癌组织(P<0.05),PgP、GST-π在三种癌中的表达无差异;三种耐药基因的共表达在淋巴结有转移中的表达明显高于无转移组(P<0.05),而与癌症类型无相关性;Ki-67的表达与三种耐药基因无明显相关。结论:肺癌的耐药与多种耐药基因蛋白介导有关,联合检测肺癌中多种耐药基因蛋白的表达,对于临床选择合理的化疗药物及防止耐药有重要意义。
Objective: To investigate the expression of PgP, ToPo-Ⅱ, GST-π and Ki-67 in lung cancer and their clinicopathological significance. Methods: The expressions of PgP, ToPo-Ⅱ, GST-π and Ki-67 in 58 cases of lung cancer were detected by immunohistochemistry (SP method). Results: The positive rates of PgP, ToPo-Ⅱ and GST-π in 58 cases of lung cancer were 17.1%, 79.1% and 72.3%, respectively. The expression of ToPo-Ⅱ in squamous cell carcinoma and small cell carcinoma was significantly higher than that of adenocarcinoma (P <0.05). There was no difference in the expression of PgP and GST-π among the three cancers. The co-expression of three drug resistance genes in lymph node metastasis was significantly higher than that in non-metastasis group (P <0.05) No correlation with the type of cancer; Ki-67 expression and three resistance genes were not significantly correlated. Conclusions: The drug resistance of lung cancer is related to the mediation of multiple drug resistance genes. The combined detection of multidrug resistance protein expression in lung cancer is of great significance in choosing appropriate chemotherapeutics and preventing drug resistance.